DiaMedica Therapeutics (DMAC) Stock: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$6.47
0.00 (0.00%)
▲
5d:
-1.37%
30d:
-5.41%
90d:
+18.5%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DMAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DMAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $6.47, which is considered oversold relative to its 30-day fair value range of $6.49 to $6.77.
Technical Outlook: Technically, DMAC is in a uptrend. Immediate support is located at $6.22, while resistance sits at $6.97.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+139.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DMAC is in a uptrend. Immediate support is located at $6.22, while resistance sits at $6.97.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+139.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.49 -
$6.77
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 139.6% below Wall St target ($15.50)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$6.49 -
$6.77
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.70
(10.8%)
Support & Resistance Levels
Support Level
$6.22
Resistance Level
$6.97
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.01
Wall Street Target
$15.50
(+139.6%)
Share & Embed Analysis
Last updated: September 14, 2026 1:59 AM ET
Data refreshes hourly during market hours. Next update: 2:59 AM
Data refreshes hourly during market hours. Next update: 2:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
